Haruta T, Kuroki S, Ohkura K, Nikami H, Nishio T, Kobayashi Y
Department of Pediatrics, Kobe General Hospital.
Jpn J Antibiot. 1994 Dec;47(12):1723-7.
The efficacy and the safety of biapenem (L-627), a new carbapenem antibiotic, against infections in pediatrics were studied. The obtained results are summarized as follows. 1. L-627 at dose levels of 5.4 mg/kg to 12.4 mg/kg (daily doses of 16.2 mg/kg to 37.2 mg/kg) was administered by intravenous drip infusion 3 times daily for 5 to 7 days to 2 cases of pneumonia, 3 cases of skin and soft-tissue infections and 1 case of urinary tract infection for a total of 6 cases. As results, all the cases showed good or better responses including 4 excellent and 2 good results. Bacteriological efficacies in all of the 3 eligible cases were assessed as "eradicated". 2. As for the safety, a decrease in the WBC count and slight elevation of GOT and GPT were observed in 1 case as abnormal changes in the laboratory tests results, only incidence of side effect observed was the eruption in 1 case. 3. The results above indicate that L-627 is useful for the treatment of general infections in pediatrics.
对新型碳青霉烯类抗生素比阿培南（L-627）治疗儿科感染的有效性和安全性进行了研究。所得结果总结如下。1. 对2例肺炎、3例皮肤和软组织感染及1例尿路感染患儿，共6例，每日3次静脉滴注比阿培南，剂量为5.4 mg/kg至12.4 mg/kg（日剂量为16.2 mg/kg至37.2 mg/kg），持续5至7天。结果显示，所有病例均有良好或更好的反应，包括4例优和2例良。3例符合条件病例的细菌学疗效均评定为“根除”。2. 安全性方面，1例实验室检查结果出现异常变化，表现为白细胞计数降低及谷草转氨酶和谷丙转氨酶轻度升高，仅1例出现皮疹这一副作用。3. 上述结果表明，比阿培南对治疗儿科常见感染有效。
